For most women at average risk, the recommended schedule is a mammogram every two years starting at age 40 and continuing through age 74. That’s the current guidance from the U.S. Preventive Services Task Force (USPSTF), which updated its recommendation in 2024 to lower the starting age from 50 to 40. Your personal schedule may differ depending on your risk factors, breast density, and which set of guidelines your doctor follows.
The Standard Schedule for Average-Risk Women
The USPSTF recommends biennial screening, meaning once every two years, for women aged 40 to 74. This applies to women at average risk who have no symptoms and no known genetic factors that increase their breast cancer risk. The every-two-year interval balances cancer detection with the downsides of more frequent screening, particularly false positives. Over a 10-year period of screening starting at age 40, women who get annual mammograms have a 61% cumulative chance of at least one false-positive result, compared with 42% for women screened every two years. The rate of benign biopsies (where tissue is removed but turns out not to be cancer) is also higher with annual screening: 7% versus 5%.
Those false positives aren’t just a statistical nuisance. Each one means a callback for additional imaging, sometimes a biopsy, and weeks of anxiety while waiting for results. For women at average risk, the USPSTF concluded that screening every two years catches nearly as many cancers while cutting those experiences roughly in half.
When Annual Screening Makes Sense
Women at high risk for breast cancer should get a mammogram every year, typically starting at age 30. The American Cancer Society defines high risk as having a lifetime breast cancer risk of roughly 20% to 25% or greater. That includes women who:
- Carry a BRCA1 or BRCA2 gene mutation, or have a parent, sibling, or child with one of these mutations
- Had radiation therapy to the chest before age 30, such as treatment for Hodgkin lymphoma
- Have certain genetic syndromes like Li-Fraumeni syndrome or Cowden syndrome, or have first-degree relatives with these conditions
- Score 20% or higher on risk assessment tools that factor in family history
For these women, the American Cancer Society also recommends a breast MRI every year in addition to the mammogram, not as a replacement. The two tests catch different things: mammograms are better at detecting tiny calcium deposits that can signal early cancer, while MRI is more sensitive to soft-tissue abnormalities, especially in dense breast tissue. Women whose lifetime risk falls below 15% don’t need MRI screening.
Why Guidelines Vary by Organization
You may notice your doctor’s recommendation doesn’t perfectly match what you read online, and that’s because major medical organizations don’t fully agree. The USPSTF says every two years for average-risk women starting at 40. The American Cancer Society has its own set of recommendations. And some professional groups, like the American College of Radiology, take a more individualized approach. The core disagreement is over where to draw the line between catching more cancers and exposing more women to false alarms and unnecessary procedures. All of them agree that screening should start no later than 40 for average-risk women.
When to Stop Screening
This question has no single answer. The USPSTF draws a firm line at age 74, saying there isn’t enough evidence to recommend screening beyond that age. The American Cancer Society takes a different approach: keep getting mammograms as long as you’re in good health and expected to live another 10 years or more. The American College of Radiology doesn’t set a hard cutoff at all, advocating instead for individualized decisions between patient and doctor.
The logic behind stopping at some point is straightforward. Breast cancers detected in older women tend to grow slowly, and competing health conditions become more likely to affect lifespan than a slow-growing tumor. But for a healthy 78-year-old with no major medical problems, the calculus is different than for someone the same age managing serious chronic illness.
Dense Breasts and Supplemental Screening
About half of women have dense breast tissue, which makes mammograms harder to read because dense tissue and tumors both appear white on the image. Many states now require that mammogram reports tell you if you have dense breasts. If you’ve received that notification, you may wonder whether you need extra screening.
For women with dense breasts but no other risk factors, the American College of Obstetricians and Gynecologists does not recommend routine supplemental testing like ultrasound or MRI. The evidence so far hasn’t shown that adding these tests reduces breast cancer deaths in this group. That said, if you have dense breasts plus other risk factors (strong family history, genetic mutations), the combination may push you into the high-risk category where annual mammograms and MRI are recommended.
3D Mammography vs. Standard Mammography
If your imaging center offers 3D mammography (also called tomosynthesis), it’s worth knowing the differences. Compared to standard 2D mammograms, 3D mammography detects about 29% more cancers overall and 44% more invasive cancers. It also reduces callback rates by about 16%, meaning fewer false alarms. The technology takes multiple X-ray images from different angles and reconstructs them into a layered view of the breast, making it easier to spot abnormalities hidden in overlapping tissue. Most screening centers now offer 3D mammography, and it doesn’t change how often you need to be screened.
What Insurance Covers
Under the Affordable Care Act, all Marketplace health plans and most other insurance plans must cover screening mammograms at no cost to you, with no copay, coinsurance, or deductible. This applies to women 40 and older for mammograms every one to two years, as long as you use an in-network provider. If your doctor recommends annual screening because of your risk level, that should still be covered as preventive care. Diagnostic mammograms, which are ordered when you have a symptom or abnormal finding, may be billed differently and could involve cost-sharing depending on your plan.